Backwaters and rapids on the amyloid river
Abstract
The advent of amyloid imaging1 has ushered in a new era for the field of Alzheimer disease (AD), opening the door for approaching previously unapproachable questions. No longer are researchers restricted to postmortem measurement of the neuropathologic hallmark of AD—amyloid plaques. Now, researchers are able to detect the presence and burden of amyloid in the living brain and examine how amyloid burden changes over time.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plaque deposition essentially occurs during the run-up to clinical AD.
“Recent data indicate plaque deposition essentially occurs during the run-up to clinical AD [216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [216]
Symptoms generally manifest only after plaques stop forming.
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [216]
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · see citing works
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works
<i>APOE</i> predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666 · see citing works
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 614 · see citing works
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · cited 1× · see citing works
“It is also important to consider, however, that if amyloid turns out to be only a secondary biomarker of the disease, as opposed to its cause, then targeting its accumulation at any stage will have, at most, a limited effect on clinical outcomes.(7) Finally, the fibrillar deposition of amyloid in the brain parenchyma…”
BackgroundSelf-citationBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works
Self-citationAmyloid precursor protein processing and bioenergetics
Wilkins, H., & Swerdlow, R. H. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.009 · Cited by 222 · see citing works
Self-citationMitochondria, Cybrids, Aging, and Alzheimer's Disease
Swerdlow, R. H., Koppel, S., Weidling, I., Hayley, C., Ji, Y., & Wilkins, H. M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.12.017 · Cited by 106 · see citing works
Self-citationBioenergetics and metabolism: a bench to bedside perspective
Swerdlow, R. H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13509 · Cited by 35 · see citing works
Self-citationContributing Factors of Neurodegeneration in Alzheimer’s Disease
Tailor, B. A., Pilozzi, A. R., & Huang, X. (2019) · Codon Publications eBooks · doi:10.15586/alzheimersdisease.2019.ch5 · Cited by 4 · see citing works
- Authors
- Burns, J. M., & Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Venue
- Neurology
- Published
- 2013-03-05
- Volume
- 80
- Issue
- 10
- Pages
- 878-879
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2108848043
- Cited by
- 5
- References
- 9
- Citations by year
- 2019: 1 · 2017: 1 · 2016: 2 · 2013: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000001)
- National Institute on Aging (R01AG033673, R01AG034614, P30AG035982)
- National Institute of Neurological Disorders and Stroke (U10NS077356, R03NS077852)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- amyloid imaging, Alzheimer's disease, amyloid plaques, amyloid burden
- MeSH terms
- Alzheimer Disease, Brain, Humans, Radionuclide Imaging, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
